Display Settings:

Format

Send to:

Choose Destination

    Am J Med. 2004 Jun 1;116(11):759-66.

    An evidence-based medicine approach to beta-blocker therapy in patients with cirrhosis.

    Talwalkar JA, Kamath PS.

    Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. talwalkar.jayant@mayo.edu

    Disease management strategies have gained attention in recent years because of their potential to improve health-related quality of life and prevent excessive resource use. Despite recognition as an important cause of mortality, cirrhosis with portal hypertension has not been widely discussed as a condition amenable to planned care management. Given the effect of variceal hemorrhage as the most immediate life-threatening complication of portal hypertension, a number of high-quality controlled clinical trials have confirmed the efficacy of beta-blocker therapy for primary and secondary prophylaxis. Despite the existence of practice guidelines that incorporate this information, specific clinical scenarios that demand consideration for beta-blocker therapy have not been well described. In this article, a number of hypothetical patient-based cases drawn from the authors' experiences are utilized to illustrate these issues.

    PMID: 15144913 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read